Interview With The CF33 Oncolytic Virus Inventor - Imugene (IMU)

TL;DR

Professor Human Fong discusses the development and potential of the CF-33 oncolytic virus, a promising treatment for various types of cancer.

Transcript

hey guys and welcome back to the asx investor channel and welcome to a very exciting interview today we're speaking to a really esteemed expert in the field and we'll be diving into the world of biotech we're really excited and grateful to be joined by the sanjaya camo family chair in surgical oncology and the chair of the city of hope department o... Read More

Key Insights

• 👨‍🔬 Professor Human Fong's extensive background in surgical oncology and research contributes to his expertise in developing the CF-33 oncolytic virus.
• ♋ The CF-33 virus is designed to selectively infect and kill cancer cells, potentially revolutionizing cancer treatment.
• 😘 CF-33 has shown remarkable potency against cancer, requiring lower doses compared to previous oncolytic viruses.
• ♋ The CF-33 virus has the potential for combination therapies and treating different types of cancer.
• ♋ Dosing the first patient with CF-33 is a significant milestone in the advancement of the virus as a potential cancer treatment.

Questions & Answers

Q: What led Professor Human Fong to pursue a career in surgical oncology?

Professor Human Fong has always been passionate about becoming a physician and surgeon, and his interest in research and literature further fueled his desire to work in the field of surgery and cancer.

Q: How does the CF-33 oncolytic virus work to kill cancer cells?

The CF-33 virus selectively infects and kills cancer cells while sparing healthy cells. It activates the immune system to recognize and attack the cancer cells, potentially leading to improved cancer treatment outcomes.

Q: What are the key benefits and advantages of the CF-33 oncolytic virus?

The CF-33 virus has shown remarkable potency against cancer, requiring significantly lower doses compared to previous generations of oncolytic viruses. It also demonstrates good potential for combination therapies and the ability to treat various types of cancer.

Q: What is the significance of the first patient being dosed with CF-33?

The dosing of the first patient marks a major milestone in the development of CF-33 as a potential cancer treatment. It allows researchers to gather crucial data on the safety and efficacy of CF-33 in humans.

Summary & Key Takeaways

• Professor Human Fong has a background in surgical oncology and extensive experience in liver and pancreatic surgery.

• The CF-33 oncolytic virus has been licensed by Immugene and shows potential to selectively kill cancer cells.

• The virus was developed through a process of combining vaccine strains and high throughput screening to identify the most effective strains.